Back to top
more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$102.19 USD

102.19
7,915,567

+0.45 (0.44%)

Updated May 31, 2024 04:03 PM ET

After-Market: $102.20 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth B Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 40% (99 out of 250)

Industry: Medical - Products

Better trading starts here.

Zacks News

Insulet (PODD) Q3 Earnings Beat, 2023 Sales Growth View Up

Insulet's (PODD) third-quarter 2023 revenues increase year over year as a result of continued high demand for Omnipod 5.

Inari Medical (NARI) Q3 Earnings and Revenues Beat Estimates

Inari Medical's (NARI) third-quarter results benefit from strong product adoption and geographical performances.

AMN Healthcare (AMN) Q3 Earnings and Revenues Beat Estimates

AMN Healthcare's (AMN) dismal results in all its segments led to a soft overall third-quarter performance.

Cardinal Health (CAH) Beats on Q1 Earnings, Ups '24 EPS View

Cardinal Health's (CAH) first-quarter fiscal 2024 results benefit from the Pharmaceutical segment's solid performance.

Stryker (SYK) Q3 Earnings Beat on Strong Segmental Result

Stryker's (SYK) third-quarter earnings reflect strong performance across its segments and geographies. However, unfavorable currency movement hurts sales growth, and rising costs affect margins.

Fresenius Medical (FMS) Q3 Earnings Miss, Operating Margin Up

Fresenius Medical's (FMS) third-quarter revenues suffer due to unfavorable currency movement. However, the company's transformational plans continue to benefit its operating income.

Investors Heavily Search Abbott Laboratories (ABT): Here is What You Need to Know

Recently, Zacks.com users have been paying close attention to Abbott (ABT). This makes it worthwhile to examine what the stock has in store.

Penumbra (PEN) Q3 Earnings Top Estimates, Margins Increase

Penumbra's (PEN) vascular and neuro product categories continue to show encouraging growth trends.

Avanos (AVNS) Q3 Earnings Top Estimates, Margins Contract

Despite strength in Avanos' (AVNS) Digestive Health segment, its overall third-quarter results reflect soft performances.

QuidelOrtho (QDEL) Q3 Earnings Top Estimates, Margins Down

Despite solid performances by the Labs and TM segments and China and Other regions, QuidelOrtho (QDEL) reports soft overall top-line results in third-quarter 2023.

Nevro (NVRO) Q3 Earnings Top Estimates, FY23 Revenue View Up

Nevro's (NVRO) worldwide revenues improve on a year-over-year basis in the third quarter, owing to robust domestic performance.

Cencora (COR) Q4 Earnings Top, GLP-1 Drugs Boost Sales

Cencora's (COR) fourth-quarter fiscal 2023 results benefit from overall market growth, including rising demand for GLP-1 drugs approved for diabetes and weight loss. Inflationary pressure remains.

Exact Sciences (EXAS) Q3 Earnings Beat, Gross Margin Rises

Exact Sciences' (EXAS) Screening revenue upside is primarily attributable to broad-based momentum in Cologuard adoption.

Baxter (BAX) Beats on Q3 Earnings, Divests BioPharma Business

Baxter (BAX) reports better-than-expected third-quarter earnings and sales. The company completes the divestment of its BioPharma Solution business. It starts reporting under a new operating model.

DENTSPLY SIRONA (XRAY) Beats on Q3 Earnings, Lowers '23 Guidance

DENTSPLY SIRONA's (XRAY) Q3 revenues are driven by a rise in demand for aligners and CAD/CAM in the United States and a recovery in demand in China. Challenging macro headwinds linger.

Glaukos (GKOS) Q3 Earnings Beat Estimates, Revenues Rise Y/Y

Glaukos' (GKOS) third-quarter revenues beat estimates but fall year over year. Sales and gross margin improve, while higher operating expenses lead to a wider operating loss.

McKesson (MCK) Beats on Q2 Earnings, Raises '23 EPS View

McKesson's (MCK) second-quarter fiscal 2024 results benefit from growth in the United States. Divestment hurts the International segment.

CVS Health (CVS) Q3 Earnings Surpass Estimates, Margins Up

Robust sales growth across all three operating segments drove CVS Health's (CVS) third-quarter results.

PacBio (PACB) Tops on Q3 Earnings, Raises FY23 Revenue View

PacBio (PACB) witnesses strong revenue growth in the third quarter, partly aided by customers' continued product transition to the Revio system.

Ecolab (ECL) Q3 Earnings Surpass Estimates, Margins Rise

Ecolab's (ECL) robust performance across all segments drives its third-quarter sales despite business challenges.

Sheraz Mian headshot

Top Stock Reports for JPMorgan Chase, Home Depot & Salesforce

Today's Research Daily features new research reports on 16 major stocks, including JPMorgan Chase & Co. (JPM), The Home Depot, Inc. (HD) and Salesforce, Inc. (CRM).

Avantor (AVTR) Q3 Earnings In-Line With Estimates, Revenues Top

Despite Avantor's (AVTR) continued stability in end markets, it reports an overall soft third-quarter performance.

Revvity (RVTY) Misses on Q3 Earnings, Lowers '23 EPS View

Revvity's (RVTY) third-quarter results reflect the impact of increased market uncertainty. The company's earnings and sales miss their respective estimates.

Integer Holdings (ITGR) Q3 Earnings Top Estimates, FY23 View Up

Integer Holdings' (ITGR) third-quarter results reflect robust Medical Sales, along with strength in the majority of the product lines.

Merit Medical (MMSI) Q3 Earnings Top Estimates, FY23 View Revised

Merit Medical (MMSI) benefits from revenue growth in both segments and all product categories within its Cardiovascular unit in the third quarter.